04:37 PM EST, 11/10/2025 (MT Newswires) -- Mineralys Therapeutics ( MLYS ) reported a Q3 loss late Monday of $0.52 per diluted share, narrowing from a loss of $1.13 a year earlier.

Analysts polled by FactSet expected a loss of $0.61.

As of Sept. 30, cash and cash equivalents were $593.6 million, expected to fund the company's clinical trials and regulatory activities, as well as operations into 2028.